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Dear Editor,
Psychiatric disorders may be secondary to endocrinological 
diseases what may be represented by the association between 
thyroid gland function and behavior manifestations. Thyroid 
hormones are widely arranged in brain and may influence some 
psychic symptoms, mainly by changing neurotransmitters’ 
release.1
We would like to report a case of a high school student, 17 
years old, who presented with agitation, insomnia, tremors, 
disinhibited behavior, exalted mood, grandiose delusion and 
auditory hallucinations for three months. He had never been 
in a psychiatry service before. His relatives reported no family 
history of psychiatric disorder. In admission, the patient exhibited 
an expansive attitude, dysphoria and accelerated thoughts. He 
reported diary cannabis abuse for the last year. After one month 
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using risperidone 2mg every day the patient returned home with 
remission of all psychotic symptoms, but still presented exalted 
mood. His follow-up in the outpatient clinic evidenced tremors, 
hypertension (AP 140x100mmHg) and tachycardia (CF 110bpm) 
for two months. Laboratory tests showed elevated thyroxin and 
reduced TSH. The patient received propiltiouracil and propranolol 
and after 45 days he presented remission of physical and psychic 
symptoms, besides stopping cannabis use.
There have been reports showing association between 
hyperthyroidism and cannabis abuse as well as with psychiatric 
disorders.1-3 Yet, there has been no association between cannabis 
use and hyperthyroidism. Animal models, however, demonstrated 
that acute cannabinoid administration disrupts many hormone 
systems, including suppression of gonadal steroids, growth 
hormone, prolactin and thyroid hormones, besides the 
hypothalamic-pituitary-adrenal axis. These effects are caused by 
endogenous cannabinoid receptors located close to and inside the 
hypothalamus.4 
Although all the consequences of chronic cannabis use in 
human endocrine system are still unclear, there is evidence that 
in thyrotoxicosis the number of binding sites for catecholamines 
increases. This report shows the importance of laboratory 
tests for thyroid diseases in patients with mood disorders.4 
Establishing a differential diagnosis is essential to conduct the best 
psychopharmacological treatment aiming at the best treatment 
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response.2 We conclude by saying that it is advisable to consider 
thyroid dysfunction as an important differential diagnosis or 
associated comorbidity in drug abuse.
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Is the Fagerström Test for 
Nicotine Dependence a 
good instrument to assess 
tobacco  use in patients with 
schizophrenia?
O Teste de Fagerström para Dependência 
de Nicotina é um bom instrumento para 
avaliar o uso de tabaco em pacientes com 
esquizofrenia?
Dear Editor,
We have read with great interest the article by Chaves and 
Shirakawa,1 in which the authors confirmed previous observations 
that patients with schizophrenia smoke in a higher rate as compared 
to the general population. They also observed that the patients 
were considered as heavy smokers according to the Fagerström 
Tolerance Questionnaire (FTQ).
Although the FTQ is considered to be adequate to assess nicotine 
dependence due to its extensive use, it suffers from significant 
psychometric shortcomings, such as low internal consistency and 
poor criterion validity.2 In order to address these problems, the 
Fagerström Test for Nicotine Dependence (FTND) was developed. 
The modifications of the FTQ consisted in the elimination of two 
items (“nicotine content of cigarette”; “frequency of inhalation”) 
